Formulation Development
EXECUTIVE INTERVIEW – TC BioPharm: Developing Platform Allogeneic Gamma-Delta T Cell Therapies for Cancer
Bryan Kobel, CEO of TC BioPharm, discusses his company’s upcoming plans, therapeutic clinical trials, and the biotech landscape.
FORMULATION DEVELOPMENT – Understanding CBD Formulation Versus Dosage Format
Gerry McNally, PhD, says there are many misconceptions when it comes to considering the best way or format to consume CBD and get the maximum benefit. Formulation scientists need to consider several factors when developing new formulations of nutraceutical ingredients, especially botanical ingredients and natural materials from various sources.
THERAPEUTIC FOCUS – Addressing the Unmet Need for Improved Treatments of Female Cancers
Martin Lehr, MA, explains how his company is advancing a pipeline of innovative products designed to address treatment resistance in breast, ovarian, and endometrial cancer, which, if approved, could provide patients with a much-needed new treatment options.
CLINICAL TRIALS – The Mission to Increase Diverse Clinical Trial Participation
Lauren Chazal, MBA, and Keidra Gaston, MBA, believe clinical trials are critical to advancing medical knowledge and new therapeutics; however, it is important that participants in clinical trials represent their entire communities and the potential recipients of new treatments.
PATIENTS-ON-A-CHIP – Why Artificial Intelligence Will Be the Tipping Point to Remove the Faulty Reliance on Animal Testing in Drug Discovery
Isaac Bentwich, MD, believes Advanced Bio-AI platforms that integrate artificial intelligence and machine learning with patients-on-a-chip, real-time nano-sensing, and stem cell genomic diversity technologies are the future of drug discovery and development.
2023 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
MACHINE LEARNING – Applying Machine Learning Techniques: Gaining Meaningful Life Sciences Insights From Genomics Data
Lucas Glass explains how the predictive capabilities offered by ML solutions can help pharmaceutical and biotech companies shift focus onto additional experiments — providing an opportunity to catch or generate potential options.
ARMED ONCOLYTIC VIRUSES – Instant Messaging Cancer With a TGF-Beta Trap Carrying Oncolytic Adenovirus
Bryan Oronsky, MD, PhD, says cancer is a systemic disease, the eradication of which heavily depends on immune responses. In his opinion, to overcome impaired immune cell function and, hence, to increase the responsiveness to CIs likely requires a 3-in-1 therapy.
DRUG DISCOVERY – Leveraging the Human Gut as a Drug Discovery Tool
Bridget Ann Martell MA, MD, says leveraging a patented technology that uses the human gut as a drug discovery tool has led to a new class of transformative precision therapeutics that disrupt inflammatory disease triggers — gut exclusive microbial metalloprotease inhibitors (GEMMI).
DRUG DELIVERY – Using the IPEG™ Delivery System to Topically Treat Rare Diseases in Dermatology While Limiting Systemic Absorption
Zachary Rome, Jessica Raiz, MPH, and Alan M. Mendelsohn, MD, are advancing innovative clinical research that is evaluating high-potential, low-risk treatments for rare dermatologic diseases using unique topical vehicles combined with established medications that enable the targeted delivery of therapies to the epidermis and dermis while minimizing systemic absorption.
EXCLUSIVE ONLINE CONTENT
Pantherna & Evaxion Announce Promising Preclinical mRNA Vaccine Data
Evaxion Biotech A/S and Pantherna Therapeutics GmbH recently announced preclinical proof of concept for the combination of the two companies’ key….
Nectin Therapeutics to Collaborate With Merck on Clinical Trial of Anti-PVR Antibody in Combination with KEYTRUDA in Patients With Locally Advanced & Metastatic Solid Tumors
Nectin Therapeutics Ltd. recently announced it has entered into a clinical trial collaboration agreement with Merck. Under this collaboration, Nectin will evaluate the safety, tolerability, and antitumor activity of its novel….
Revive Therapeutics Enters Research Collaboration Agreement With PharmaTher for Development of MDMA Transdermal Patch
Revive Therapeutics Ltd. recently announced it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxymethamphetamine (MDMA) using PharmaTher’s novel microneedle….
Purple Biotech Expands Pipeline of First-in-Class Therapeutics With Acquisition of Immunorizon & Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
Purple Biotech Ltd. recently announced it has entered into an agreement for the acquisition of Immunorizon Ltd., a private company developing potential multi-specific T and NK cell engager oncology therapies that….
X-Chem & Kymera Expand Existing Partnership
X-Chem recently announced the expansion of its collaboration with Kymera Therapeutics, Inc. With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded….
MARKET NEWS & TRENDS
WEBINARS
ON-DEMAND WEBINAR – CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza
Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….
WEBINAR – Getting to the Core of Pellet Coating
This webinar is part of The future of solid dosage, an ACG 360 webinar series covering wide-ranging, simple, and transformative ways to achieve smarter pharma formulation, manufacture, and packaging.
WEBINAR – Hot-Melt Granulation Technology for Lipid-Based Pharmaceuticals
Join our experts Dr. Mandar Kodgule, Dr. Rahul Aware, and Dr. Agnivesh Shrivastava live as they take you through compelling case studies, current trends and developments, and insights on mastering the design of hot-melt granulation process.
ON-DEMAND WEBINAR – Exploring Pectin & the Advancement of Delayed Release Technology
In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
WEBINAR – Understanding Patch Composition for Effective Transdermal Delivery
As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….
WHITE PAPERS
WHITEPAPER – Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening
A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop….
WHITEPAPER – Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)
Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets…..
WHITEPAPER – Maintaining Sustainable Business Practices During the Energy & Supply Crisis
As we come to the end of another year, our global economy faces many significant challenges. Recently, a colleague asked me, “As a biopharma executive, which of today’s major issues are the ones that keep you up at night?”
WHITEPAPER WORKSHOP – Soft Mist Inhalers
Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition…..
WHITEPAPER – Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development
Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more….